Efforts include support for earlier diagnosis through LAMairTM, TrilliumBiO's newly developed VEGF ‐ D test ROCKVILLE, Md. and CINCINNATI , June 29, 2026 /PRNewswire/ -- TrilliumBiO, a leader in biomarker discovery and precision diagnostics, today announced a commitment to raising awareness of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women. As part of this effort, the company is proud to highlight its partnership with The LAM Foundation, the global